Catabasis Pharmaceuticals Культура компании

Ms. Deirdre A. Cunnane, J.D. has been Senior Vice President and General Counsel at Catabasis Pharmaceuticals, Inc. since November 2015 and has been its Principal Financial Officer since June 30, 2016. Ms. Cunnane serves as Treasurer at Catabasis Pharmaceuticals, Inc. Ms. Cunnane has been the Supervisory Attorney for the Harvard Law Entrepreneurship Project (HLEP) since September 2014. She served as a General Counsel at Advanced Technology Ventures from January 2006 to October 2015. She joined the Advanced Technology Ventures in 2006 to provide legal counsel in connection with investments, fund management and corporate matters. She also served as the General Counsel at Lightstone Ventures from January 2012 to October 2015. She was an Investment Officer at BancBoston Ventures, Inc., where she was responsible for managing venture and buy-out investments in healthcare, high-tech and retail industries. She served as the Deputy General Counsel at BancBoston Capital, Inc. having joined in 1998. She structured, reviewed and negotiated terms of equity and debt investments and management buy-outs in a $1 billion portfolio which included significant direct investments in private equity, mezzanine and venture funds in healthcare, high-tech and retail industries. She started her legal career at Goodwin, Procter & Hoar LLP (Goodwin Procter LLP), where she later became a Partner and for nine years represented venture capital and private equity investors in debt and equity financings and recapitalization transactions. She also advised emerging growth companies and provided legal counsel in connection with mergers and acquisitions. She has more than 25 years of legal experience specific to venture capital and private equity issues. Ms. Cunnane holds a J.D. degree from Boston College Law School and a B.S. degree in Finance from the School of Management at Boston College.

Dr. Andrew J. Nichols, also known as Andy, Ph.D. has been the Chief Scientific Officer at Catabasis Pharmaceuticals, Inc. since October 5, 2016 and served as its Senior Vice President of Research & Non-Clinical Development from November 14, 2015 to October 5, 2016. Dr. Nichols served as Senior Vice President of Research at Catabasis Pharmaceuticals, Inc. from September 24, 2015 to November 14, 2015 and served as its Vice President of Research from February 26, 2014 to September 24, 2015. Prior to joining Catabasis, Dr. Nichols served as an Associate Vice President of cardiometabolic diseases at Merck Research Laboratories, leading drug discovery and early clinical development programs. Dr. Nichols served as Head of Preclinical Biology at Zafgen, Inc. Dr. Nichols served as Vice President of Preclinical Research at Zafgen Inc. He has more than 25 years experience in the pharmaceutical industry. He served as Vice President of Discovery Alliances for Alinea Pharmaceuticals Inc. He served as Vice President of Discovery Project Leadership for Millennium Pharmaceutical Inc., with responsibility for the strategy and execution of the full portfolio of drug discovery projects. He led the Metabolic Disease Biology group and served as the Senior Program Director for the Metabolic and Cardiovascular Disease Programs. He served various positions including Director, Alliance Management in the Alliance and Technology Group and Assistant Director, Cardiovascular Pharmacology at SmithKline Beecham Pharmaceuticals and responsible for progressing three compounds to IND. Dr. Nichols received his B.Sc. in pharmacology from the University of Leeds, England and his M. Phil. and Ph.D. in cardiovascular pharmacology from the University of Cambridge in Cambridge, England.

Dr. Michael Jirousek, also known as Mike, Ph.D., serves as Chief Operating Officer of Frequency Therapeutics, Inc. Dr. Jirousek co-founded Catabasis Pharmaceuticals, Inc., in June 2008 and served as its Chief Scientific Officer and Secretary until September 2015. Dr. Jirousek has more than 20 years of experience in pharmaceutical research and development. Dr. Jirousek served as Senior Vice President of Research at Sirtris Pharmaceuticals, Inc., since September 12, 2006. He served in the pharmaceutical industry with a focus on drug discovery for more than fifteen years. He joined Sirtris from Pfizer La Jolla where he founded and led the Diabetes and Obesity Therapeutic Area. Prior to Pfizer, he served research positions at Abbott Laboratories and also Eli Lilly where he led groups focused in the metabolic field. He has been a Member of Scientific Advisory Board at Catabasis Pharmaceuticals, Inc., since October 31, 2015. Dr. Jirousek has worked on a variety of drug discovery and development projects resulting in co-invention of and/or responsibility for bringing nine compounds (biologics and small molecules) into clinical trials for diabetes, diabetic complications, obesity and cancer. He is active in several professional societies including the American Diabetes Association, Juvenile Diabetes Research Foundation and the American Chemical Society. He has co-authored over 160 peer reviewed publications, patents and abstracts. Dr. Jirousek has a Ph.D. in Chemistry from Case Western Reserve University with Robert Salomon and was a postdoctoral fellow at Harvard University with Yoshito Kishi and a B.S. in chemistry from Kent State University.

Dr. Joanne M. Donovan, M.D., Ph.D. has been the Chief Medical Officer of Catabasis Pharmaceuticals, Inc. since July 2011. Dr. Donovan serves as Senior Vice President of Clinical Development at Catabasis Pharmaceuticals, Inc. Dr. Donovan has deep experience in the biotechnology industry. Prior to joining Catabasis, she held increasing leadership roles at Genzyme Corporation, where she was Vice President of clinical research. She led multiple programs in clinical and preclinical development, including in cardiovascular-lipid lowering, metabolism and gastroenterology. In addition, she served as the medical lead for multiple business development activities, including out-licensing initiatives and diligence assessments. Dr. Donovan was brought into Genzyme through the acquisition of GelTex where she led multiple clinical programs. Dr. Donovan serves as an Associate Clinical Professor of Medicine at Harvard Medical School. She is also a staff physician at the Boston Veteran's Administration Medical Center, where she formerly was chief of gastroenterology. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology and an M.D. from Harvard Medical School. She completed her postdoctoral training at Brigham and Women's Hospital.

Angelika Fretzen serves as the Senior Vice President, Product Development of Catabasis Pharmaceuticals, Inc.. Angelika started at Catabasis Pharmaceuticals, Inc. in October of 2014. Angelika currently resides in Greater Boston Area.

Noah Clauser serves as the Vice President, Finance of Catabasis Pharmaceuticals, Inc.. Noah started at Catabasis Pharmaceuticals, Inc. in August of 2017. Noah currently resides in Greater Boston Area.

John Holtz serves as the Executive Director of Catabasis Pharmaceuticals, Inc.. John started at Catabasis Pharmaceuticals, Inc. in January of 2016. John currently resides in Greater Boston Area.

Rafif Dagher serves as the Executive Director of Catabasis Pharmaceuticals, Inc.. Rafif started at Catabasis Pharmaceuticals, Inc. in July of 2017. Rafif currently resides in Greater Boston Area.

Andrea Matthews serves as the Vice President, Corporate Affairs of Catabasis Pharmaceuticals, Inc.. Andrea started at Catabasis Pharmaceuticals, Inc. in August of 2017. Andrea currently resides in Greater Boston Area.